Alzheimer's drugs that inhibit the enzyme acetylcholinesterase to increase the availability of acetylcholine are limiting what process?

Acetylcholinesterase enzyme inhibitors are limiting the hydrolysis process of the neurotransmitter acetylcholine, increasing its availability and interaction with specific receptors.

Explanation:

Acetylcholine is a neurotransmitter that aims to stimulate or inhibit the activity of a tissue, by stimulating nicotinic and muscarinic receptors. An example of this is the action of acetylcholine on nicotinic receptors present in the muscle, which promote muscle contraction.

Acetylcholinesterase is responsible for hydrolyzing acetylcholine to make the effect on a receptor end.

In degenerative diseases of the nervous system -such as Alzheimer's- the activity of acetylcholine decreases, so reversible acetylcholinesterase inhibitors are used to limit the neurotransmitter hydrolysis process, increase its bioavailability, and allow the effect of acetylcholine on muscarinic brain receptors.

Learn more:

link